Phase II study on the combination of irinotecan plus cisplatin as a second‑line therapy in patients with advanced or recurrent gastric cancer

Rino,Yasushi; Yukawa,Norio; Sato,Tsutomu; Oshima,Takashi; Tanabe,Hiroyasu; Yamamoto,Yuji; Matsukawa,Hiroshi; Shiraishi,Ryuji; Imada,Toshio; Masuda,Munetaka

doi:10.3892/mco.2013.115

July-August 2013 Volume 1 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-August 2013 Volume 1 Issue 4

Full Size Image

Article

Phase II study on the combination of irinotecan plus cisplatin as a second‑line therapy in patients with advanced or recurrent gastric cancer

Authors:
- Yasushi Rino
- Norio Yukawa
- Tsutomu Sato
- Takashi Oshima
- Hiroyasu Tanabe
- Yuji Yamamoto
- Hiroshi Matsukawa
- Ryuji Shiraishi
- Toshio Imada
- Munetaka Masuda
View Affiliations / Copyright

Affiliations: Department of Surgery, School of Medicine, Kanazawa-ku, Yokohama 236-0004, Japan, Department of Gastroenterology, Medical Center, Yokohama City University, Minami-ku, Yokohama 232‑0024, Japan, Department of Surgery, Kamishirane Hospital, Asahi‑ku, Yokohama 241‑0002, Japan, Department of Surgery, Kanagawa Prefectural Ashigarakami Hospital, Ashigarakami‑gun, Kanagawa 258‑0003, Japan, Department of Surgery, Yokohama Minami Kyosai Hospital, Kanazawa-ku, Yokohama 236‑0037, Japan, Department of Surgery, Hiratsuka Kyosai Hospital, Hiratsuka, Kanagawa 254‑0047, Japan, Saiseikai Yokohamasi Nanbu Hospital, Konan-ku, Yokohama 234‑0054, Japan
Pages: 749-752
|
Published online on: May 9, 2013

https://doi.org/10.3892/mco.2013.115
Expand metrics +

Abstract

Α pilot phase II study was conducted to evaluate the efficacy and safety of the combined administration of irinotecan (CPT‑11) plus cisplatin (CDDP) as a second‑line therapy for advanced or recurrent gastric cancer. Between November, 2006 and May, 2009, 18 patients were enrolled in this study. The patients were required to have received prior chemotherapy with S‑1 (n=17), an orally administered 5-fluorouracil (5-FU) prodrug, or S‑1 plus CDDP (n=1). CPT‑11 and CDDP were administered at a dose of 60 and 30 mg̸m2, respectively, on days 1 and 15 of a 4‑week treatment cycle. The regimen was repeated until the occurrence of unacceptable toxicity, disease progression, or patient refusal. The primary endpoint of this study was the response rate (RR). In the second‑line setting, 2 cases of complete response (CR), 1 of partial response (PR) and 7 of stable disease (SD) were identified. The RR was 16.7% and the disease control rate (DCR) was 55.6%. The median survival time (MST) and progression‑free survival (PFS) was 282 and 111 days, respectively. As regards hematological toxicity, the major adverse effect during the second‑line of chemotherapy was grade 3‑4 leukopenia (22.2%). In addition, with regard to non‑hematological toxicities, the major adverse effect during the second‑line chemotherapy was grade 3‑4 loss of appetite (11.1%). there was no mortality attributable to the adverse effects of the drugs. Findings of the present study suggested that CPT‑11 and CDDP combination therapy in a second‑line setting is an effective regimen in the treatment of advanced gastric cancer.

View Figures

View References

1.	Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
2.	Boku N, Yamamoto S, Fukuda H, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
3.	Japanese Gastric Cancer Association: Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 14:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Koizumi W, Kurihara M, Satoh A, et al: Phase I/II study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer. Anticancer Res. 25:1257–1262. 2005.PubMed/NCBI
5.	Ajani JA, Rodriguez W, Bodoky G, et al: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 28:1547–1553. 2010. View Article : Google Scholar
6.	Rino Y, Yukawa N, Murakami H, et al: A phase II study of S-1 monotherapy as a first-line combination therapy of S-1 plus cisplatin as a second-line therapy, and weekly paclitaxel monotherapy as a third-line therapy in patients with advanced gastric carcinoma: a second report. Clin Med Insights Oncol. 4:1–10. 2010. View Article : Google Scholar
7.	Oba M, Chin K, Kawazoe Y, et al: Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens. Oncol Lett. 2:241–245. 2011.
8.	Oba M, Chin K, Kawazoe Y, et al: Availability of irinotecan in second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens. Oncol Lett. 2:247–251. 2011.PubMed/NCBI
9.	Nakae S, Hirao M, Kishimoto T, et al: Phase II study of bi-weekly CPT-11+CDDP for patients with gastric cancer refractory to S-1 (OGSG 0504 study). J Clin Oncol. 26:(May 20 suppl; abstr 4571),. 2008.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Phase II study on the combination of irinotecan plus cisplatin as a second‑line therapy in patients with advanced or recurrent gastric cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles